ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Advancing The Development Of Syringe-Device Combinations

  Defining the design for syringe-autoinjector pairings early, through shared compatibility testing, can reduce integration risk for high-viscosity biologics intended for self-administration at home.

• Redefining Patient-Centric Drug Delivery

  Preloaded on-body delivery systems reduce user error risks during treatment, while patient preference data supports simpler, more reliable home administration.

• Why Early Device Decisions Matter: How Immunovant Accelerated Its Program

  Deferring autoinjector selection can seem to preserve flexibility, yet it often moves constraints downstream. Integrating the device during Phase IIb changed one program's timeline and removed bridging work.

• For The Record: How Past Experience Enables Future Success

  Launch counts and years in business prove a partner has delivered, but the better question is what was learned along the way and how much carries forward.

• Navigating The Analytical Challenges Of Complex ADCs

  Antibody drug conjugates are expanding to deliver diverse therapeutic payloads. Advanced analytical strategies are required to characterize these evolving platforms.

• Getting Ahead Of PFAS Risk In Pharmaceutical Manufacturing

  Pharma can’t simply eliminate essential PFAS uses. A phased, risk-based strategy can address footprint, exposure, and supply risks amid regulatory uncertainty.

• A Risk Management Approach For The Pharmaceutical Industry

  Replacing fluorinated chemistries across pharma isn’t simple. Growing pressures make it critical to prioritize risks and take a sequenced, evidence-based approach to mitigation.

• High-Performing Ionizable Lipids For Controlled Nucleic Acid Delivery

  Ionizable lipids are central to effective mRNA delivery, influencing potency, biodistribution, and toxicity. See why advancing delivery beyond the liver will require stronger structure-function insights.

• What Downstream Deviations Reveal About Upstream Process Maturity

  Fill finish deviations can reveal upstream process issues early. Identifying these signals helps reduce variability, improve process control, and strengthen sterile injectable manufacturing.

• The People Who Turn An Idea Into A Deliverable Product

  Drug developers and device engineers share more common ground than their distinct disciplines suggest, facing parallel pressures around design, safety, regulatory approval, and scalable performance.